Clinical Efficacy - Eczema Itch Improvement Information for Health Care Professionals

Clinical efficacy – Itch improvement

Atopiclair efficacy in infants and children – improves itch³

Study design: 139 children aged 6 months to 12 years with mild to moderate flare symptoms were treated 3 times a day in a randomized, double-blind, vehicle-controlled study. Children were treated with either Atopiclair or vehicle (cream base without Atopiclair key ingredients) for 43 days.

Itch relief significantly better than vehicle as early as day 3 and at all time points measured during the 43-day study (P<.0001)
78% improvement in itch with Atopiclair on day 43
The most frequently reported adverse events in the Atopiclair-treated vs vehicle-treated groups were burning (6.9% vs 7.1%) and stinging (8.3% vs 2.8%)

Atopiclair efficacy in adults — improves itch²

Study design: 218 adults with mild to moderate flare symptoms were treated 3 times a day in a randomized, double-blind, vehicle-controlled study. Patients were treated with either Atopiclair or vehicle (cream base without Atopiclair key ingredients) for 50 days.

Itch relief significantly better than vehicle — 82% improvement in itch score with Atopiclair at day 50
The most frequently reported adverse events in Atopiclair treated vs vehicle-treated groups were common cold (5.5% vs 6.8%) and rash (2.1% vs 5.5%)

>>Reduces Rescue Medication Use

Important Safety Information
For external use only; avoid contact with eyes.

Under the supervision of a health care professional, Atopiclair nonsteroidal cream is indicated to manage and relieve the itching, burning and pain experienced with various types of dermatoses, including atopic dermatitis and allergic contact dermatitis. Atopiclair nonsteroidal cream helps to relieve dry, waxy skin by maintaining a moist skin environment, which is beneficial to the healing process.

Atopiclair nonsteroidal cream does not contain milk, wheat, peanut or animal derivatives. Atopiclair nonsteroidal cream does contain shea butter (butyrospermum parkii), a derivative of shea nut oil (not peanut oil). Patients with a known allergy to nuts or nut oils should consult their physician before using this topical preparation.

Frequently reported adverse events in Atopiclair-treated and vehicle-treated groups were burning (6.9% vs 7.1%) and stinging (8.3% vs 2.8%).